Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today, we learn the NCI is planning to study ivermectin for cancer, despite significant scientific evidence suggesting it’s a dead end. The FDA rejected a gene therapy from Regenexbio, and Novo Nordisk gets serious about prosecuting compounders.
Among other things, Novo maintains it’s not easy to make copycat versions of its drugs easily and safely, which may be underscored by the fact that a compounder Hims & Hers acquired not long ago was apparently sanctioned by the FDA after its facilities were found to be harboring vermin. Continue to STAT+ to read the full story…